Zimmer Biomet Holdings Stock Performance
| ZBH Stock | USD 110.73 1.05 0.94% |
Zimmer Biomet has a performance score of 3 on a scale of 0 to 100. The firm maintains a market beta of 0.11, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Zimmer Biomet's returns are expected to increase less than the market. However, during the bear market, the loss of holding Zimmer Biomet is expected to be smaller as well. Zimmer Biomet Holdings right now maintains a risk of 1.51%. Please check out Zimmer Biomet Holdings skewness, and the relationship between the value at risk and day median price , to decide if Zimmer Biomet Holdings will be following its historical returns.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Zimmer Biomet Holdings are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite fairly strong fundamental drivers, Zimmer Biomet is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
Actual Historical Performance (%)
One Day Return (0.94) | Five Day Return (1.55) | Year To Date Return 6 | Ten Year Return (2.71) | All Time Return 283.55 |
Forward Dividend Yield 0.0087 | Payout Ratio | Last Split Factor 103:100 | Forward Dividend Rate 0.96 | Dividend Date 2025-04-30 |
1 | Acquisition by Shapiro Louis of 130 shares of Zimmer Biomet at 105.73 subject to Rule 16b-3 | 12/31/2024 |
2 | Acquisition by Michael Farrell of 301 shares of Zimmer Biomet at 107.76 subject to Rule 16b-3 | 01/06/2025 |
3 | Surgical Robotics, AI Integration, and Minimally Invasive Surgery Propel Growth of Global Surgical Equipment Market, Valued at 56.6 Billion by 2029 | 02/10/2025 |
4 | Disposition of 2383 shares by Sang Yi of Zimmer Biomet subject to Rule 16b-3 | 02/20/2025 |
5 | Acquisition by Suketu Upadhyay of 19090 shares of Zimmer Biomet subject to Rule 16b-3 | 02/27/2025 |
6 | Zimmer Biomet Holdings Appoints Kristen Cardillo As Chief Communications Officer | 03/06/2025 |
7 | Dental Implant Market Forecast Report and Company Analysis 2025-2033 Featuring Danaher, Dentsply Sirona, Institut Straumann, Zimmer Biomet, Kyocera, Henry Schei... | 03/07/2025 |
8 | Acquisition by Michael Farrell of 307 shares of Zimmer Biomet at 105.73 subject to Rule 16b-3 | 03/10/2025 |
9 | Zimmer Biomet Holdings Inc Trading Down 3.05 percent on Mar 11 | 03/11/2025 |
10 | Orthopedics Robotic-Assisted Surgery Industry Forecast 2025-2035 - By 2035, Cost-Effective Robotic Systems Will Propel Market Expansion in Emerging Regions | 03/12/2025 |
11 | Global Biosensors Market Poised for Robust Growth, Projected to Reach USD 76.2 Billion by 2035 with a CAGR of 9.1 percent Future Market Insights, Inc. | 03/18/2025 |
| Begin Period Cash Flow | 415.8 M |
Zimmer |
Zimmer Biomet Relative Risk vs. Return Landscape
If you would invest 10,706 in Zimmer Biomet Holdings on December 24, 2024 and sell it today you would earn a total of 367.00 from holding Zimmer Biomet Holdings or generate 3.43% return on investment over 90 days. Zimmer Biomet Holdings is generating 0.0666% of daily returns assuming volatility of 1.5124% on return distribution over 90 days investment horizon. In other words, 13% of stocks are less volatile than Zimmer, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Zimmer Biomet Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Zimmer Biomet's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Zimmer Biomet Holdings, and traders can use it to determine the average amount a Zimmer Biomet's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.044
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | ZBH | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.51 actual daily | 13 87% of assets are more volatile |
Expected Return
| 0.07 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average Zimmer Biomet is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Zimmer Biomet by adding it to a well-diversified portfolio.
Zimmer Biomet Fundamentals Growth
Zimmer Stock prices reflect investors' perceptions of the future prospects and financial health of Zimmer Biomet, and Zimmer Biomet fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Zimmer Stock performance.
| Return On Equity | 0.0725 | ||||
| Return On Asset | 0.0465 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 27.72 B | ||||
| Shares Outstanding | 199.06 M | ||||
| Price To Earning | 77.41 X | ||||
| Price To Book | 1.77 X | ||||
| Price To Sales | 2.87 X | ||||
| Revenue | 7.68 B | ||||
| Gross Profit | 5.5 B | ||||
| EBITDA | 2.25 B | ||||
| Net Income | 452.4 M | ||||
| Cash And Equivalents | 375.7 M | ||||
| Cash Per Share | 2.71 X | ||||
| Total Debt | 6.2 B | ||||
| Debt To Equity | 0.48 % | ||||
| Current Ratio | 1.98 X | ||||
| Book Value Per Share | 62.62 X | ||||
| Cash Flow From Operations | 1.5 B | ||||
| Earnings Per Share | 4.43 X | ||||
| Market Capitalization | 22.04 B | ||||
| Total Asset | 21.37 B | ||||
| Retained Earnings | 11.1 B | ||||
| Working Capital | 2.22 B | ||||
| Current Asset | 5.85 B | ||||
| Current Liabilities | 1.62 B | ||||
About Zimmer Biomet Performance
By evaluating Zimmer Biomet's fundamental ratios, stakeholders can gain valuable insights into Zimmer Biomet's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Zimmer Biomet has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Zimmer Biomet has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 372.35 | 263.09 | |
| Return On Tangible Assets | 0.12 | 0.17 | |
| Return On Capital Employed | 0.07 | 0.06 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.07 | 0.07 |
Things to note about Zimmer Biomet Holdings performance evaluation
Checking the ongoing alerts about Zimmer Biomet for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Zimmer Biomet Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Zimmer Biomet has a strong financial position based on the latest SEC filings | |
| Over 94.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Global Biosensors Market Poised for Robust Growth, Projected to Reach USD 76.2 Billion by 2035 with a CAGR of 9.1 percent Future Market Insights, Inc. |
- Analyzing Zimmer Biomet's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Zimmer Biomet's stock is overvalued or undervalued compared to its peers.
- Examining Zimmer Biomet's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Zimmer Biomet's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Zimmer Biomet's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Zimmer Biomet's stock. These opinions can provide insight into Zimmer Biomet's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Zimmer Stock analysis
When running Zimmer Biomet's price analysis, check to measure Zimmer Biomet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zimmer Biomet is operating at the current time. Most of Zimmer Biomet's value examination focuses on studying past and present price action to predict the probability of Zimmer Biomet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zimmer Biomet's price. Additionally, you may evaluate how the addition of Zimmer Biomet to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |